Previous 10 | Next 10 |
2024-02-16 17:56:00 ET More on AbbVie, Cerevel Therapeutics, etc. AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding AbbVie: Game Changer AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq Dividend Roundup: Target, Meta Pl...
2024-02-12 08:14:34 ET AbbVie ( NYSE: ABBV ) has updated its earnings outlook for the first quarter of 2024 to reflect a dilutive impact related to its acquisition of cancer drugmaker ImmunoGen ( NASDAQ: IMGN ).... Read the full article on Seeking Alpha For f...
2024-02-10 20:30:24 ET Summary Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntingto...
2024-02-09 15:00:09 ET More on the markets SPY: Larger Treasury Issuances And Fewer Fed Cuts Are Not Priced In My Current View Of The S&P 500 Index: February 2024 Edition (Technical Analysis) 2024 Analyst Outlook: Yiannis Zourmpanos On Cautious Optimism For The N...
2024-02-08 05:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-06 16:05:44 ET Summary AbbVie Inc. is showing signs of growth beyond the loss of exclusivity for Humira, with strong 2024 guidance. Sales of Skyrizi and Rinvoq are replacing lost Humira sales, with projected sales more than doubling through 2027. AbbVie's acquisitions ...
2024-02-02 08:22:44 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...
2024-02-01 12:10:01 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...
2024-01-29 08:30:18 ET More on AbbVie AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen Investor's Dilemma: AbbVie Stock Amidst U.S. Election And Humira Decline Big Pharma earnings season in...
2024-01-28 12:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are enco...